about
The epidermal growth factor receptors and their family of ligands: their putative role in atherogenesisProduction of a novel camel single-domain antibody specific for the type III mutant EGFR.A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell linesTreatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells.Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival.Epitope mapping of epidermal growth factor receptor (EGFR) monoclonal antibody and induction of growth-inhibitory polyclonal antibodies by vaccination with EGFR mimotope.Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cellsMolecular therapy of head and neck cancer.Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition.Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.Expression pattern and targeting of HER family members and IGF-IR in pancreatic cancer.Therapeutic application of monoclonal antibodies in cancer: advances and challenges.Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells.Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers.Analysis of the immunomodulatory properties of two heat-killed mycobacterial preparations in a human whole blood model.Resveratrol 3-O-D-glucuronide and resveratrol 4'-O-D-glucuronide inhibit colon cancer cell growth: evidence for a role of A3 adenosine receptors, cyclin D1 depletion, and G1 cell cycle arrest.Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib.Production and characterization of a new antibody specific for the mutant EGF receptor, EGFRvIII, in Camelus bactrianus.Inhibitory Effects of Culinary Herbs and Spices on the Growth of HCA-7 Colorectal Cancer Cells and Their COX-2 Expression.GA201: a novel humanized and glycoengineered anti-EGFR antibody--letter.EGF mediates monocyte chemotaxis and macrophage proliferation and EGF receptor is expressed in atherosclerotic plaquesAntitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptorThe expression of p53, c-erbB-1 and c-erbB-2 molecules and their correlation with prognostic markers in patients with head and neck tumorsPeriadventitial delivery of anti-EGF receptor antibody inhibits neointimal macrophage accumulation after angioplasty in a hypercholesterolaemic rabbitAmplification and expression of EGFR and ERBB2 in Wilms tumorDevelopment and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic cancer
P50
Q24312466-CE295DA5-7797-455D-970A-9E1CED460973Q31138512-B7FBC418-0D36-41F7-B94A-34CBCD540121Q33605906-AE29283D-195A-46F6-9ECE-11C8C6D90FAAQ33822560-FD0CDB00-7501-47C0-B6F7-8A0AA644B638Q34569071-13FAD1FD-A504-44B1-9488-E2F62328FEE3Q35114983-06B99132-BCC9-42AC-8D07-AE81E2087323Q35214496-96130EA9-E4CE-4280-9782-621C8ED4EDDAQ35623056-BFC27C55-AA16-4FA7-8D78-7C516A4C14D0Q36078112-89187539-31DC-49B7-BB11-3B1807A58C63Q36571455-B243D1F9-BC1F-4859-90F7-4349E5B48DD6Q37337898-507C4D3B-9887-4E16-A5C0-4A1137D35CC1Q37614156-4564735D-03AD-4927-A74E-710931ED1BACQ38015157-CD0856A2-7A4A-4FF0-97FD-6AEE5D79C7A9Q38057179-F8423E4F-2449-4E5A-8EA8-0AFE83F8D6B5Q38303537-01626660-A233-47BB-8578-99103FA795D6Q38835146-FFA381D6-7967-43A1-80A7-E0AA98DA12D5Q38976563-448B77C7-D503-4C99-B143-C6479FD57FF5Q39155351-5C296967-8DDB-4E28-B1DD-B5B81CE11F1CQ40248491-2F1BF01D-0BAF-4D4E-AD5A-7D199E92F2C1Q40489069-B81DFD64-CA3E-42DE-9E32-CDF6DC5EE8FBQ44255281-3A0D7D14-3F80-4F7C-B46E-31DDFCEDF3A5Q54376483-27358888-4DF9-4C08-A4BF-9D07D8DE4C0FQ58417445-7212AB21-6D12-4224-AE15-06A736E9A4DCQ71680646-000821AE-2695-4A0B-8571-04D28F98748FQ74486048-02A1A9C0-4CAA-4858-9C39-7BE77D14AB55Q82210330-EC71071A-5167-4B8A-8ABE-2F43346F22C1Q84587812-29D77CAC-B0EF-4EE7-B333-858902B8A177Q92740298-7015EDD8-6FF3-43DF-956B-D074317AA62E
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Helmout Modjtahedi
@ast
Helmout Modjtahedi
@en
Helmout Modjtahedi
@es
Helmout Modjtahedi
@nl
Helmout Modjtahedi
@sl
type
label
Helmout Modjtahedi
@ast
Helmout Modjtahedi
@en
Helmout Modjtahedi
@es
Helmout Modjtahedi
@nl
Helmout Modjtahedi
@sl
prefLabel
Helmout Modjtahedi
@ast
Helmout Modjtahedi
@en
Helmout Modjtahedi
@es
Helmout Modjtahedi
@nl
Helmout Modjtahedi
@sl
P106
P1153
55917154800
P31
P496
0000-0002-5509-7415